Drug intelligence / Profile preview

Awaytox

Development stage: Unknown
Lead developer: Steadfast Medishield
Modality: Small Molecules, Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**Awaytox** is a commercially marketed oral synbiotic renal-nutrition product from Steadfast Medishield. It combines the probiotic organisms *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Streptococcus thermophilus* at 5 billion CFU each with 100 mg lactitol monohydrate, a prebiotic carbohydrate. The product is intended to support intestinal microbiota and reduce the intestinal generation or absorption of uremic nitrogenous toxins in patients with chronic kidney disease, including those receiving dialysis. ([steadfast.co.in](https://www.steadfast.co.in/awaytox/))

Brand names: Awaytox

Beyond the preview

Go deeper on Awaytox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Awaytox.

Explore the full profile